Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNRNP200 | O75643 | 3/20 | 0.51 |
| ▸ | IDH1 | O75874 | 9/20 | 0.34 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 3/20 | 0.32 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16857040 | 0.88 | SNRNP200 (0.56) | SNRNP200 | |
| SCHEMBL15592758 | 0.88 | SNRNP200 (0.56) | SNRNP200 | |
| SCHEMBL16856880 | 0.88 | SNRNP200 (0.56) | SNRNP200 | |
| SCHEMBL16857334 | 0.88 | SNRNP200 (0.47) | SNRNP200IDH1SLC8A1NR1I2AKT1 | |
| SCHEMBL15592841 | 0.87 | SNRNP200 (0.55) | SNRNP200 | |
| SCHEMBL16856827 | 0.86 | SNRNP200 (0.49) | SNRNP200IDH1NR1I2AKT1 | |
| SCHEMBL16857216 | 0.84 | SNRNP200 (0.54) | SNRNP200 | |
| SCHEMBL16857182 | 0.83 | SNRNP200 (0.52) | SNRNP200IDH1 | |
| SCHEMBL16857308 | 0.83 | SNRNP200 (0.55) | SNRNP200IDH1 | |
| SCHEMBL16856997 | 0.82 | SNRNP200 (0.55) | SNRNP200IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2889291-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-07-01 | — | — | EP | disclosed |
| EP-2889291-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | PTGIS, LIPG, FEN1 | SNRNP200 3216/4885IDH1 3193/4885SLC8A1 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.